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Abstract                           
Introduction: Apoptosis is an important mechanism in both physiological and pathological 
conditions. The BCL2 family of proteins plays a critical role in regulation of apoptotic cell 
death. Up and down regulation of BCL2-like 12 (BCL2L12), a new member of the BCL2 
family, has been reported in several malignancies. However, the expression level of 
BCL2L12 rarely has been studied in leukemia. This study was designed to investigate the 
mRNA expression of BCL2L12 in patients with acute leukemia. 
Materials and methods: 90 patients with acute leukemia as case group and 90 healthy 
persons as controls, were participated this study. RNA was extracted from peripheral blood 
samples. Expression level of BCL2L12 mRNA was evaluated by a quantitative real-time 
polymerase chain reaction (qRT-PCR) method and its association with clinical and laboratory 
findings was analyzed. 
Results: The expression of BCL2L12 mRNA was significantly lower in acute lymphoblastic 
leukemia (ALL) cases comparing the controls (P<0.001), while it was not significantly 
different in acute myeloid leukemia (AML) samples compared the control group. In addition, 
there were higher BCL2L12 level in females (than in males) and in patients with t(12;21) in 
ALL patients. There was no association between BCL2L12 expression level and other 
clinical and laboratory findings of AML patients. 
Conclusion: BCL2L12 seems play a role in the pathogenesis of ALL.  Further studies with 
larger sample size is needed to clarify its probable impact on prognosis and therapeutic 
response. 
Keywords: Acute myeloid leukemia, Acute lymphoblastic leukemia (ALL), BCL2L12, 
Apoptosis 
Introduction 
Apoptosis is an important mechanism in 
physiological conditions, such as 
embryonic development and tissue 
homeostasis as well as pathological 
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conditions, such as cancer, 
neurodegenerative conditions and 
autoimmune diseases (1-3). Aberration in 
apoptotic pathways is one of the key 
components in the pathogenesis of lots of 
malignancies (1, 4), including acute and 
chronic leukemias (2, 5, 6). In addition 
dysregulation of normal programmed cell 
death mechanisms plays an important role 
in cancer chemoresistance (7-8). The 
BCL-2 family is one of the most important 
regulators of apoptosis, containing both 
anti-apoptotic and pro-apoptotic members 
(1, 9). The pro-apoptotic members of the 
BCL2 family, including BAX, BAD, BID, 
and BCLXS, induce apoptosis, whereas 
the anti-apoptotic members, such as BCL2, 
BCLXL, and BCLW, suppress the 
apoptotic machinery (2-4). Over 
expression of anti-apoptotic members of 
the Bcl-2 family such as Bcl-2 and Bcl-xL 
has been implicated in resistance to 
chemotherapy, whereas over expression of 
pro-apoptotic proteins such as Bax 
promotes apoptosis and sensitizes tumor 
cells to various anticancer drugs (10-13). 
The BCL2-like 12 (BCL2L12) protein, a 
novel member of this family, structurally 
consists of a highly conserved BH2 
domain, a BH3-like domain, and a prolin 
rich domain (5, 12). BCL2L12 gene is 
located in 19q13.3 and composed of 7 
coding exons and 6 intros which yield to a 
334 amino acid long protein (12).To date, 
the precise function of BCL2L12 gene has 
not been determined and there are 
controversial data demonstrating that 
BCL2L12 involved in both pro- and anti-
apoptotic mechanisms (14).The BCL2L12 
has been studied in several malignancies 
including chronic lymphocytic leukemia 
(CLL) (12), glioblastoma (15), 
nasopharyngeal carcinoma (16), breast 
cancer (17), and gastric cancer (18, 19).   
However, BCL2L12 mRNA expression 
rarely been studied in acute leukemia. 
Acute leukemias are a heterogeneous 
group of hematopoietic malignancies with 
varying morphologic characteristics (20). 
Acute lymphoblastic leukemia (ALL) is 
the most common malignant neoplasm 
diagnosed in children younger than 15 
years, accounting for about 25% of all 
cancers and 75% of all leukemias in this 
age group. Approximately 80% of adult 
onset acute leukemias are acute myeloid 
leukemia (AML) (21). Based on the 2008 
revision of World Health Organization 
(WHO) classification of acute leukemias, 
cytogenetic abnormalities are one of the 
most important criteria for diagnosis and 
prognosis of acute leukemias (20-22). In 
addition to cytogenetic abnormalities, 
several other genetic alterations such as 
over expression of the anti-apoptotic 
proteins of the BCL2 family have been 
proposed as important prognostic factors 
(23). Konopleva et al. reported that Bcl-2 
can be contributed to the survival and 
chemoresistance of CD34 positive 
leukemia cells (24).  Moreover, a 
correlation between high Bcl-2 expression 
and poor response to chemotherapy has 
been reported in AML (25-27). In addition 
it has been shown that suppression of Bcl-
2 expression promotes apoptosis and 
sensitizes AML cells to chemotherapy 
(26). In contrast, a relationship between 
high expression of BCL2 and increased 
disease-free survival in childhood ALL 
(29), as well as high BCL2 expression and 
higher complete remission rates in adults 
ALL have been reported (30). Moreover, 
elevated BCL2 expression is a good 
predictive factor for corticoresistance in T-
ALL (31). 
As mentioned, data by different studies in 
various cancers, underlines the role of 
BCL2L12 in cancer genesis and behavior. 
However, the role of this protein in acute 
leukemias is not completely determined 
yet. There are only few reports about the 
association between BCL2L12 and AML; 
and also, to the best of our knowledge, 
studies about evaluation of BCL2L12 
mRNA expression in patients with ALL 
have not been reported. Regarding these 
data, BCL2L12 mRNA expression by 
quantitative real-time polymerase chain 


































    
    














 ]  
Original article                                                              J Bas Res Med Sci 2016; 3(2):11-19 . 
13 
 
leukemia patients was evaluated in this 
study attempting to find its probable role 
in the pathogenesis of the disease.  
Furthermore, the association between 
BCL2-like12 expression level and other 
laboratory and clinical findings of patients 
was analyzed. 
Materials and methods 
Study included 90 morphologically 
confirmed, newly diagnosed acute 
leukemia patients (45 AML and 45 ALL), 
who were admitted to Qaem University 
Hospital, Mashhad, Iran since October 
2012 to march 2014. The diagnosis of 
acute leukemias were made based on the 
WHO criteria (i.e. more than 20% blasts in 
the peripheral blood smear or bone 
marrow). AML and ALL were 
differentiated using cytochemistry staining 
and flow cytometric studies. According to 
the French–American–British (FAB) 
criteria, the AML and ALL subtypes were 
classified morphologically.   Patients who 
had received treatment and samples with 
low RNA quality were excluded. Ninety 
age and sex matched healthy individuals 
were included in the study as controls (45 
as AML controls and 45 as ALL controls). 
The study protocol was approved by the 
Research Ethics Committee in Mashhad 
University of Medical Sciences. A written 
informed consent was obtained from each 
individual. 
Four milliliters of the peripheral blood of 
the patients and the controls were collected 
in 2 sterile tubes containing K2–EDTA 
anticoagulant for RNA extraction and 
morphologic examination. Demographic 
characteristics (e.g. age, and gender), 
clinical data (including splenomegaly, 
hepatomegaly and lymphadenopathy) and 
lab data (e.g. complete blood count 
findings and recurrent genetic 
abnormalities) were obtained via a 
questionnaire filled by trained personnel or 
patients’ hospital data. 
RNA extraction and cDNA synthesis: 
The mononuclear blood cells of patients 
and controls were isolated from their 
peripheral blood samples using Ficoll 
gradient centrifugation. Total RNA was 
extracted by RNX plus™ kit (Cinnagen, 
Tehran, Iran) according to the 
manufacturer’s instructions.  The quality 
and quantity of the extracted RNA was 
evaluated by agarose gel electrophoresis. 
Total RNA was reversely transcribed using 
cDNA synthesis kit (thermo scientific, 
Lithuania).  
BCL2L12 expression analysis: The PCR 
primers for BCL2L12 or Beta-2-
microglobolin (B2M) were designed (23) 
as follows: BCL2L12 (gene of interest) 
forward, 3'- CCCTCGGCCTTGCTCTCT-
5' and reverse, 3'-
GGGCCACCAAAGCATAGAAG-5'. 
B2M (housekeeping or reference gene) 
forward, 3'-CAGCAAG 
GACTGGTCTTTCTAT-5' and reverse, 3'- 
GCGGCATCTTCAAACCTC-5 .' 
Real-time polymerase chain reactions were 
carried out using thermocycler (Applied 
Biosystems, Foster City, CA, USA) and 
SYBR green method by the means of 
TAKARA Master Mix (Japan). The 
reaction mixture was prepared by adding 
10 µl Master Mix, 0.5 µl of each primer, 2 
µl cDNA, 0.4 µl of Rox and 7.1 µl of 
nuclease free water in a total volume of 20 
µl. The thermal conditions of the study 
consisted of an initial pre-denuturatun at 
95 °C for 10 min followed by 40 cycles of 
denaturation at 95°C for 40 seconds, 
annealing at 60°C for 30 seconds, 
extension at 72°C for 30 seconds, and a 
final extension at 72°C for 5 min. 
The relative BCL2L12 mRNA expression 
was calculated using the PCR threshold 
cycle number (CT) or comparative Ct 
(ΔΔCt) method. The relative fold change 
in gene expression = 2 -ΔΔCt, Where: 
ΔΔCt = ΔCt patients –ΔCt control group 
and ΔCt = Ct target gene (BCL2l12) – Ct 
reference gene (B2M) (42). In this method 
the amplification efficiencies of the 
BCL2L12 (Gene of interest) and reference 
genes must be approximately equal. In our 
study BCL2L12 and B2M PCR 
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Statistical analysis  
Data management and analysis was 
performed using SPSS (Statistical software 
for social analysis-version 11.5). The 
Kolmogorov–Smirnov test was applied to 
determine normality of data distribution 
and then, independent sample t-test and 
analysis of variance test (ANOVA test) 
were used for comparing continuous 
variables (such as levels of BCL2L12 
mRNA) between the groups. Chi-Square 
was used to compare the non continuous 
variables and Pearson correlation test were 
used to determine relationship between 
variables. Differences were considered 
statistically significant at P<0.05. 
Results  
Twenty nine males and 16 females with 
median age of 43.02 years were 
participated in the AML group and 26 
(57.8%) male and 19 (42.2%) female were 
included in the AML control group with 
median age of 45.59 years. There were no 
significant differences between the case 
and control groups in sex and age (P=0.13 
and P=0.56, respectively). The 
morphologic subtypes of AML consisted 
of 7 M1 (%15.6) ,10 M2 (%22.2), 7 M3 
(%15.6),  12 M4 (%26.7) and 9 M5 
samples. The genetic study revealed 
t(15;17) in 7 patients (%15.6), t(8;21) in 2 
patient (%4.4), and inv(16) in 1 patient 
(%2.2). The clinical data exhibited 
splenomegaly in 15 (33.3%), 
hepatomegaly in 6 (13.3%) and 
lymphadenopathy in 1 (2.2%) of patients. 
Twenty males (44.4%) and 25 females 
(55.6%), with a median age of 14.66 years 
at the time of diagnosis were consisted in 
the ALL group. In addition, the ALL 
control group was composed of 22 males 
(48.9%) and 23 females (51.1%), with a 
median age of 15.34 years. There were no 
significant differences between the ALL 
patients and control group in sex and age 
(P=0.26 and P=0.83, respectively). The 
morphologic subtypes of ALL consisted of 
27 L1 (%60.0) and 18 L2 (%40.0) 
samples. The genetic study demonstrated 
t(12;21) in 7 (%10.3) patients, t(9;22) in 6 
(%8.8) patients, and t(1;19) in 2 (%2.9) 
patients. Splenomegaly was seen in 19 
(27.9%), hepatomegaly in 12 (17.6%) and 
lymphadenopathy in 17 (22.1%) of 
patients.  
The mean ± standard deviation (SD) level 
of BCL2L12 mRNA (or BCL2L12 mRNA 
copies/B2M mRNA copies) was 7.11 ± 
2.35 (ranged from 2.91 to 11.01) in the 
samples of AML patients and 6.15 ± 1.96 
(ranged from 1.791 to 10.15) in the 
samples of ALL patients. The mean levels 
of BCL2L12 mRNA expression in controls 
of AML and ALL were 7.62 and 7.69, 
respectively.  
The t test showed no significant difference 
between the AML patients and control 
group (P = 0.15) in BCL2L12 mRNA 
expression but the mean level of BCL2L12 
mRNA in ALL cases was significantly (P 
< 0.001) lower than the control group 
(6.15 vs 7.69).  
Tables 1 and 2 show mean level of 
BCL2L12 expression in different 
subgroups of patients (based on age, sex, 
…). There were not any statistically 
significant differences between BCL2L12 
mRNA expression in different age and sex 
groups in AML cases and also in age 
groups in ALL patients. However the 
mean level of BCL2L12 mRNA in males 
were significantly (P = 0.01) lower than 
females (5.2 vs 6.6) in ALL cases. 
There were not any significant relationship 
between BCL2L12 expression and blood 
hemoglobin (P=0.82), RBC (P=0.85), 
WBC (P=0.78), PLT (P=0.20) in ALL 
cases and also between BCL2L12 and 
blood hemoglobin (P=0.82), RBC 
(P=0.42), WBC (P=0.31), PLT (P=0.89) 
age in ALL patients.  Seven patients with 
t(12;21) positive in ALL group had 
significantly (P = 0.009) higher BCL2L12 
expression compare to patients without  
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Table 1. The mean levels of BCL2L12 mRNA expression in different subgroups of the AML patients. 
 Number(percent) Mean BCL2L12 mRNA expression P value 
Sex    0.78 
       male  29 7.19 ± 2.27 
 female 16 6.98 ± 2.56 
Age (year)   0.16 
       <50 28 7.51 ± 2.19 
 >50 17 6.45 ± 2.51 
Splenomegaly   0.41 
       yes 15 6.70 ± 2.39 
 no 30 7.32 ± 2.34 
Hepatomegaly   0.76 
       yes 6 6.76± 3.13 
 no 39 7.17± 2.25 
Lymphadenopathy   0.72 
       yes 10 6.88 ± 2.32 
 no 35 7.18 ± 2.39 
FAB subtype   0.63 
       M1 7 5.90 ± 2.37 
 M2 10 7.18 ± 2.49 
 M3 7 7.79 ± 2.50 
 M4 12 7.09 ± 2.52 
 M5 9 7.11 ± 1.96 
t(8;21)   0.58 
       yes 2 6.52± 1.17 
 no 43 7.14 ± 2.39 
t(15;17)     0.45 
       yes 7 7.79 ± 2.50 
 no 38 6.99 ± 2.33 
Inv 16     0.15 
       yes 1 10.48 
 no 44 7.04 ± 2.32 
 
Table 2. The mean levels of BCL2L12 mRNA expression in different subgroups of the ALL patients. 
 Total Mean BCL2L12 mRNA expression P value 
Sex    0.01 
       male  20 5.23 ± 1.83 
 female 23 6.69 ± 1.67 
Age (year)   0.25 
       <10 25 6.45 ± 1.84 
 >10 20 5.76 ± 2.08 
Splenomegaly   0.12 
       yes 19 5.56 ± 1.41 
 no 26 6.51 ± 2.24 
Hepatomegaly   0.10 
       yes 12 5.41± 1.60 
 no 33 6.41± 2.03 
Lymphadenopathy   0.59 
       yes 15 6.38 ± 2.19 
 no 30 6/03 ± 1.87 
FAB subtype   0.84 
       L1 27 6.20 ± 1.86 
 L2 18 6.07 ± 2.16 
t(12;21)   0.009 
       yes 7 8.37± 1.87 
 no 38 5.73 ± 1.70 
t(9;22)     0.85 
       yes 6 6.23 ± 0.92 
 no 39 6.13 ± 2.08 
t(1;19)     0.60 
       yes 2 6.65 ± 1.03 
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BCL2-like-12 gene (BCL2L12) cloned by 
Scorilas et al. in 2000; is a newly 
identified member of the BCL2 family. 
Up- and down- regulated BCL2L12 
expression levels have been reported in 
various malignancies (13,16, 34). To the 
best of our knowledge, importance and 
prognostic impact of BCL2L12 in acute 
leukemias have not been completely 
clarified yet.  
This study was done on 90 patients with de 
novo acute leukemia and 90 healthy 
controls. We detected significantly lower 
levels of BCL2L12 mRNA in ALL 
samples versus control samples (p =0.001). 
In addition the BCL2L12 mRNA 
expression level was lower in AML group 
than the controls (7.11 vs. 7.62) but the 
differences were not statistically 
significant. In line to our study Thomadaki 
et al. examined the expression of this gene 
in 21 patients with de novo AML and did 
not find significant differences (p=0.14) 
between case and control groups (5.75 vs. 
14.82) (35). In contrast to our results, Yu 
et al. reported a significantly (P < 0.01) 
lower level of BCL2L12 gene expression 
in 134 AML patients compared to control 
group (36). Although BCL2L12 
expression in our AML patients was lower 
than control group (7.11 vs. 7.62) but the 
differences were not statistically 
significant. Lower BCL2L12 mRNA 
expression has been reported in other 
malignancies such as breast cancer (37) 
and higher BCL2L12 mRNA levels have 
been detected in CLL (15, 40), 
Nasopharyngeal carcinoma (16), bladder 
carcinoma (34). The dissimilarity between 
relative BCL2L12 expression in our study 
comparing the other studies (such as 
Thomadaki et al study) may be the result 
of using different reference genes; While 
we used B2M, they employed GAPDH as 
internal control (reference) gene.  
We did not find any article concerning 
relations between the levels of BCL2L12 
mRNA with acute lymphoblastic 
leukemia. Similar study was done on 
relations between the levels of Bcl-2 with 
acute leukemia (29-31). In the ALL group, 
we found a higher BCL2L12 level in 
females (than in males) and in patients 
with t(12;21). In addition we did not find 
any association between BCL2L12 
expression level and any of the clinical and 
laboratory findings of AML patients.  In a 
similar study, Thomadaki et al. did not 
find any relationship between BCL2L12 
expression level and hepatomegaly 
(P=0.23), FAB classification (P=0.31) and 
hemorrhagic syndrome (P=0.44) however 
they demonstrated an association between 
BCL2L12 expression level and 
splenomegaly (P=0.04) (35). 
The impact of other BCL2L12 family 
proteins, such as BCL2 has been 
investigated in AML, too. It has been 
demonstrated that BCL2 expression was 
associated with hyperleukocytosis and also 
M4 and M5 subtypes of AML (31, 40). 
Higher mean BCL-2 expression in newly 
diagnosed AML patients (M1, M2 FAB 
subtypes) compared to controls has been 
reported by El-Shakankiry et al. using 
western blotting (40). 
Interestingly, it has been suggested 
recently that BCL2L12 may be used as a 
new biomarker in specific types of cancers 
(16). Furthermore, it has been 
demonstrated that BCL2L12 over 
expressed breast cancer patients are less 
likely to develop relapse or die in 
comparison to down regulated patients 
(17). In nasopharyngeal carcinoma the 
high BCL2L12 expression level was 
associated with more aggressive forms of 
the disease (18). In contrast with CLL and 
nasopharyngeal carcinoma, BCL2L12 
expression in gastric and breast cancers 
was correlated with favorable prognosis 
(18-19). 
Although it has shown that BCL2L12 
interacts with the p53 tumor suppressor, 
but the functional role of BCL2L12 
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by Steghet et al. demonstrated that 
BCL2L12 inhibits binding of P53 to 
promoter elements of its target genes. 
Additionally they reported that BCL2L12 
reduces p53 protein stability in response to 
DNA damage (15). Regarding the function 
of BCL2L12 in apoptosis, BCL2L12 may 
play a role in pathogenesis of malignancies 
such as acute leukemias.  
Conclusion: This study showed that 
expression of BCL2L12 mRNA was 
significantly lower in ALL comparing the 
controls, while it was not significantly 
different in AML samples comparing the 
control group. Our finding suggested that 
BCL2L12 may play an important role in 
pathogenesis of ALL but it seems that 
BCL2L12 do not contribute in the 
pathogenesis of AML. Further studies with 
larger sample sizes as well as follow up of 
the patients is needed to clarify the exact 
role of BCL2L12 in the tumor genesis of 
acute leukemias and its probable effect on 
prognosis and resistance to therapy.   
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